The 340B Program is Growing, But is it Benefitting Patients?

The Berkeley Research Group recently published an updated report that compared sales across federal prescription drug programs, to put the size of the 340B Program into perspective. The study found that in 2022, total 340B program sales reached $54.6 billion, when measured at the discounted 340B price, which is more than double the level of 340B sales compared to five years prior. This growth is likely driven by an increase in participation in the program, hospital and provider consolidation, and expansion of contract pharmacy arrangements.

Just that figure alone does not adequately represent the size of the 340B program as 340B prices were an average of 57% lower than list prices in 2022 and the discounted 340B price for...

Today's Sponsors

Today's Sponsor